Today, Quadramed (QDHC) became the second stock profiled by the Sirtuin Investor to receive an all cash buyout offer. While it wasn't at the 100% premium that Sirtris Pharmacueticals obtained from Glaxo last year, at $8.50 cash per share it represents a healthy 33% premium over Quadramed's closing price of $6.41 and a 93% annualized return since the company was profiled by Sirtuin Investor on July 28, 2009. It's difficult to determine if a bidding war will start but it is certainly a possibility.
Congratulations to all who did their own due diligence and purchased shares.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment